Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transcatheter Cardiovascular Therapeutics 2004 Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Guidant SPIRITed by study results: MACE rate of 7.7% at six months for Guidant's drug-eluting stent is slightly higher - but statistically comparable - to rates associated with J&J/Cordis' Cypher and Boston Scientific's Taxus. At the Sept. 27-Oct. 1 TCT 2004 conference in Washington, D.C., Guidant releases six-month data from the 60-patient, randomized, single-blind SPIRIT-FIRST trial, showing angiographic in-stent late loss of 0.10 mm for the everolimus-elutingversion of the MultiLink Vision stent, versus 0.84 mm for bare-metal. Both of the major adverse cardiac events (2/23) linked to the DES occurred within the first 30 days, with no new events out to six months, Guidant notes. SPIRIT-FIRST tests a cobalt-chromium, durable-polymer stent system - a departure from Guidant's FUTURE trials assessing a stainless-steel stent platform with bioabsorbable-polymer. The study supports an IDE filing for a pivotal trial (1"The Gray Sheet" Sept. 20, 2004, p. 6)...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts